ArticleMetabolomics : Official journal of the Metabolomic Society2025
Diagnostic screening of COVID-19 based on multiomics data by high-resolution mass spectrometry (MALDI (+)-TOF MS and ESI(±)-Orbitrap MS).
Article in Metabolomics : Official journal of the Metabolomic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe urgency for rapid diagnostics during the COVID-19 pandemic in 2020 highlighted the importance of effective methods such as RT-PCR, however multiomics analyses offer a more comprehensive approach, going beyond simple viral detection to the biological understanding of the disease.
objectivethis study aimed to devise an effective multiomic method for differentiating SARS-CoV-2-infected patients, leveraging serum lipid and proteomic profiles.
methodElectrospray ionization mass spectrometry (ESI-MS) with an Orbitrap analyzer was used to investigate the lipid profile of 239 serum samples (119 positive and 120 negative for test ELISA for COVID-19). Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was used to analyze the proteomic profile of 300 serum samples (150 positive and 150 negative for test ELISA for SARS-CoV-2). After processing MS data and selecting variables, statistical analyses such as the Volcano plot, Heatmap, Principal Component Analysis (PCA), Partial Least Squares Discriminant Analysis (PLS-DA), and Support Vector Machine (SVM) were performed to distinguish the most relevant variables to classify samples that presented or did not present antibodies for SARS-CoV-2.
resultsLipidomics analysis using ESI(±)-Orbitrap MS and SVM models, showed sensitivities of 96.67% and 100%, specificities of 82.14% and 96.88%, and accuracies of 89.66% and 98.44% for positive and negative ion mode analyses, respectively. For Proteomics analyses using MALDI(+)-TOF MS, the linear PLS-DA model demonstrated an accuracy of 99.10%.
conclusionboth ESI-Orbitrap MS and MALDI-TOF MS techniques, combined with chemometrics, demonstrated promising alternatives with high sensitivity and specificity for distinguishing the immune response. However, the investigation of the lipid profile by direct infusion ESI MS represents a valuable and efficient approach that reinforces the application of mass spectrometry in clinical diagnostics, particularly when aiming for high-throughput and minimally invasive analysis.
Indexed as
Identifiers
40581904What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.